Report cover image

Middle East and Africa Liver Fibrosis Treatment Market

Publisher Data Bridge Market Research
Published Apr 01, 2025
Length 350 Pages
SKU # DAABD20406801

Description

Middle East and Africa liver fibrosis treatment market is expected to reach USD 2,354.75 million by 2032 from USD 935.44 million in 2024, growing at a substantial CAGR of 12.3% in the forecast period of 2025 to 2032.

Market Segmentation:
Middle East and Africa Liver Fibrosis Treatment Market, By Treatment Type (Medication and Surgery/Therapy), Stages ( F2, F1, F3, and F4), Indication (Non-Alcoholic Steatohepatitis (NASH), Hepatitis B & C-Induced Fibrosis, Alcoholic Liver Disease (ALD), Autoimmune Liver Diseases, Genetic Disorders, and Others), Gender(Male and Female), End User (Hospitals, Specialty Clinics, Clinics, Ambulatory and Research Centers, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Israel and rest of Middle East and Africa) - Industry Trends & Forecast To 2032
Overview of Middle East and Africa Liver Fibrosis Treatment Market Dynamics:

Driver

• Increasing Prevalence of Liver Diseases
Restraint

• Limited Awareness of Liver Diseases
Opportunity

• Progress in Pipeline Products for Liver Fibrosis Treatment
Market Players:

The key market players operating in the Middle East and Africa liver fibrosis treatment market are listed below:

• Gilead Sciences, Inc.
• AbbVie Inc.
• Merck & Co., Inc.
• Novartis AG
• Intercept Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd
• Abbott
• La Renon Healthcare Pvt. Ltd.
• GENFIT SA
• Madrigal Pharmaceuticals
• Aligos Therapeutics
• Pfizer Inc.
• Enanta Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Vertex Pharmaceuticals Incorporated
• Takeda Pharmaceutical Company Limited
• Hepion Pharmaceuticals
• Echosens
• Galectin Therapeutics, Inc.
• Conatus Pharmaceuticals
• Tvardi Therapeutics
• Viking Therapeutics
• Calliditas Therapeutics AB
• Novomedix
• Galecto Biotech
• Pilant Therapeutics, Inc.
• Sagimet Biosciences
• Gyre Therapeutics, Inc.
• Akero Therapeutics, Inc.
• CureVac SE
• Novo Nordisk A/S
• Ipsen Pharma
• AdAlta Limited
• Alentis Therapeutics AG

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.

Table of Contents

350 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Middle East And Africa Liver Fibrosis Treatment Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Multivariate Modelling
2.6 Treatment Type Lifeline Curve
2.7 Primary Interviews With Key Opinion Leaders
2.8 Dbmr Market Position Grid
2.9 Market End User Coverage Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestal Analysis
4.2 Porters Five Forces Analysis
4.2.1 Liver Transplantation Volume And Their Cost For Liver Fibrosis By Country
4.2.2 Endoscopic & Minimally Invasive Procedures For Liver Fibrosis: Volume And Cost By Country
4.2.3 Partial Hepatectomy (Liver Resection) Cost By Country
4.2.4 Cell-based Therapy Cost For Liver Fibrosis Treatment By Country
4.3 Epidemiology
4.3.1 Incidence Of All By Gender
4.3.2 Treatment Rate
4.3.3 Treatment Rate
4.3.4 Drug Adherence And Therapy Switch Model
4.3.5 Patient Treatment Success Rates
4.4 Marketed Drug Analysis
4.5 Demographic Trends: Impacts On All Incidence Rates
4.5.1 Patient Flow Diagram
4.5.2 Key Pricing Strategies
4.5.3 Key Patient Enrollment Strategies
5 Middle East And Africa Liver Fibrosis Treatment Market: Regulations
6 Market Overview
6.1 Drivers
6.1.1 Increasing Prevalence Of Liver Diseases
6.1.2 Rising Consumption Of Alcohol
6.1.3 Rising Liver Transplantation Rates
6.1.4 Growing Incidence Of Non-alcoholic Fatty Liver Disease (Nafld) & Nash
6.2 Restraints
6.2.1 Limited Awareness Of Liver Diseases
6.2.2 Regulatory Challenges
6.3 Opportunities
6.3.1 Emerging Technologies And Advanced Treatments In Liver Fibrosis Management
6.3.2 Progress In Pipeline Products For Liver Fibrosis Treatment
6.3.3 Strategic Mergers And Acquisitions Among The Key Players
6.4 Challenges
6.4.1 Lack Of Effective And Approved Anti-fibrotic Drugs
6.4.2 High Cost Of Treatments In Liver Fibrosis Care
7 Middle East And Africa Liver Fibrosis Treatment Market, By Treatment Type
7.1 Overview
7.2 Medication
7.2.1 Antiviral Agents
7.2.1.1 Velpatasvir/Sofosbuvir
7.2.1.2 Tenofovir
7.2.1.3 Ledipasvir/Sofosbuvir
7.2.1.4 Sofosbuvir
7.2.1.5 Entecavir
7.2.2 Antifibrotic Agents
7.2.2.1 Obeticholic Acid
7.2.2.2 Tgf-β Inhibitors
7.2.2.3 Connective Tissue Growth Factor (Ctgf) Inhibitors
7.2.2.4 Lysyl Oxidase-like 2 (Loxl2) Inhibitors
7.2.2.5 Others
7.2.3 Anti-inflammatory Drugs
7.2.3.1 Corticosteroids
7.2.3.1.1 Prednisone
7.2.3.1.2 Dexamethasone
7.2.3.2 Tumor Necrosis Factor (Tnf) Inhibitors
7.2.3.2.1 Infliximab
7.2.3.2.2 Etanercept
7.2.3.3 Interleukin (Il) Inhibitors
7.2.3.3.1 Il-6 Inhibitors (Tocilizumab)
7.2.3.3.2 Il-1 Inhibitors (Anakinra)
7.2.4 Immunosuppressants
7.2.4.1 Mycophenolate Mofetil
7.2.4.2 Tacrolimus
7.2.4.3 Cyclosporine
7.2.5 Marketed Drugs
7.2.5.1 Velpatasvir/Sofosbuvir
7.2.5.2 Tenofovir
7.2.5.3 Ledipasvir/Sofosbuvir
7.2.5.4 Obeticholic Acid (Oca)
7.2.5.5 Sofosbuvir
7.2.5.6 Pirfenidone
7.2.5.7 Others
7.2.6 Pipeline Drugs
7.2.7 Branded Drugs
7.2.7.1 Epclusa
7.2.7.2 Viread And Vemlidy
7.2.7.3 Ocaliva
7.2.7.4 Harvoni
7.2.7.5 Sovaldi
7.2.7.6 Baraclude
7.2.7.7 Actos
7.2.7.8 Others
7.2.8 Generic Drugs
7.2.9 Oral
7.2.10 Parenteral
7.2.11 Others
7.3 Surgery/Therapy
7.3.1 Liver Transplantation
7.3.2 Orthotopic Liver Transplant (Olt)
7.3.3 Living Donor Liver Transplant (Ldlt)
7.3.4 Split Liver Transplantation
7.3.5 Domino Liver Transplant
7.3.6 Endoscopic & Minimally Invasive Procedures
7.3.6.1 Endoscopic Variceal Ligation (Evl)
7.3.6.2 Transjugular Intrahepatic Portosystemic Shunt (Tips)
7.3.6.3 Liver Ablation Procedures
7.3.6.3.1 Radiofrequency Ablation (Rfa)
7.3.6.3.2 Microwave Ablation (Mwa)
7.3.7 Partial Hepatectomy (Liver Resection)
7.3.7.1 Segmental Resection
7.3.7.2 Lobectomy
7.3.7.3 Wedge Resection
7.3.8 Cell-based Therapy
7.3.8.1 Stem Cell Therapy
7.3.8.1.1 Mesenchymal Stem Cells (Mscs)
7.3.8.1.2 Hematopoietic Stem Cells (Hscs)
7.3.8.2 Gene Therapy
7.3.8.2.1 Crispr-based Liver Regeneration
7.3.8.2.2 Hepatic Stellate Cell (Hsc) Inhibitors
7.3.8.2.3 Sirna-based Therapies
7.3.8.2.4 Hepatocyte Apoptosis Inhibitors
7.3.8.2.4.1 Oxidative Stress Inhibitors
7.3.8.2.4.2 Emricasan
7.3.8.2.4.3 Pentoxifylline
7.3.8.2.4.4 Losartan
7.3.8.2.4.5 Methyl Ferulic Acid
7.3.8.2.4.6 Others
7.4 Others
8 Middle East And Africa Liver Fibrosis Treatment Market, By Stages
8.1 Overview
8.2 F2
8.3 F1
8.4 F3
8.5 F4
9 Middle East And Africa Liver Fibrosis Treatment Market, By Indication
9.1 Overview
9.2 Non-alcoholic Steatohepatitis (Nash)
9.3 Hepatitis B & C-induced Fibrosis
9.3.1 Chronic Hepatitis B Virus (Hbv) Fibrosis
9.3.2 Chronic Hepatitis C Virus (Hcv) Fibrosis
9.4 Alcoholic Liver Disease (Ald)
9.5 Autoimmune Liver Diseases
9.5.1 Autoimmune Hepatitis (Aih)
9.5.2 Primary Biliary Cholangitis (Pbc)
9.5.3 Primary Sclerosing Cholangitis (Psc)
9.6 Genetic Disorders
9.6.1 Hemochromatosis
9.6.2 Wilson’s Disease
9.6.3 Alpha-1 Antitrypsin Deficiency
9.7 Others
10 Middle East And Africa Liver Fibrosis Treatment Market, By Gender
10.1 Overview
10.2 Male
10.2.1 40-55 Years
10.2.2 Above 55 Years
10.2.3 Below 40 Years
10.3 Female
10.3.1 Above 55 Years
10.3.2 40-55 Years
10.3.3 Below 40 Years
11 Middle East And Africa Liver Fibrosis Treatment Market, By End User
11.1 Overview
11.2 Hospitals
11.2.1 Public Hospitals
11.2.2 Private Hospitals
11.3 Specialty Clinics
11.3.1 Hepatology Clinics
11.3.2 Gastroenterology Clinics
11.4 Clinics
11.5 Ambulatory And Research Centers
11.6 Others
12 Middle East And Africa Liver Fibrosis Treatment Market, By Distribution Channel
12.1 Overview
12.2 Direct Tender
12.2.1 Retail Sales
12.2.1.1 Hospital Pharmacy
12.2.1.2 Retail Pharmacy
12.2.1.3 Online Pharmacy
13 Middle East And Africa Liver Fibrosis Treatment Market, By Region
13.1 Middle East And Africa
13.1.1 South Africa
13.1.2 Saudi Arabia
13.1.3 U.A.E
13.1.4 Egypt
13.1.5 Israel
13.1.6 Kuwait
13.1.7 Qatar
13.1.8 Oman
13.1.9 Rest Of Middle East And Africa
14 Middle East And Africa Liver Fibrosis Treatment Market: Company Landscape
14.1 Company Share Analysis: Global
15 Swot Analysis
16 Company Profiles
16.1 Gilead Sciences, Inc.
16.1.1 Company Snapshot
16.1.2 Revenue Analysis
16.1.3 Company Share Analysis
16.1.4 Product Portfolio
16.1.5 Recent Development/News
16.2 Abbvie, Inc.
16.2.1 Company Snapshot
16.2.2 Revenue Analysis
16.2.3 Company Share Analysis
16.2.4 Product Portfolio
16.2.5 Recent Development
16.3 Merck & Co, Inc.
16.3.1 Company Snapshot
16.3.2 Revenue Analysis
16.3.3 Company Share Analysis
16.3.4 Product Portfolio
16.3.5 Recent Development
16.4 Novartis Ag
16.4.1 Company Snapshots
16.4.2 Revenue Analysis And Segmented Analysis
16.4.3 Company Share Analysis
16.4.4 Product Portfolio
16.4.5 Pipeline Product Portfolio
16.4.6 Recent Development
16.5 Intercept Pharmaceuticals, Inc.
16.5.1 Company Snapshots
16.5.2 Company Share Analysis
16.5.3 Revenue Analysis And Segmented Analysis
16.5.4 Product Portfolio
16.5.5 Pipeline Product Portfolio
16.5.6 Recent News
16.6 Abbott
16.6.1 Company Snapshot
16.6.2 Revenue Analysis
16.6.3 Product Portfolio
16.6.4 1.1.5 Recent Development
16.7 Aligos Therapeutics
16.7.1 Company Snapshot
16.7.2 Revenue Analysis
16.7.3 Product Portfolio
16.7.4 Recent Development
16.8 Alniche Life Sciences Pvt. Ltd.
16.8.1 Company Snapshot
16.8.2 Product Portfolio
16.8.3 Recent Development
16.9 Alentis Therapeutics Ag
16.9.1 Company Snapshot
16.9.2 Pipeline Product Portfolio
16.9.3 Recent Development
16.10 Adalta Limited
16.10.1 Company Snapshot
16.10.2 Revenue Analysis
16.10.3 Pipeline Product Portfolio
16.10.4 Recent News
16.11 Akero Therapeutics, Inc.
16.11.1 Company Snapshot
16.11.2 Revenue Analysis
16.11.3 Pipeline Product Portfolio
16.11.4 Recent Development
16.12 Bristol-myers Squibb
16.12.1 Company Snapshot
16.12.2 Revenue Analysis
16.12.3 Product Portfolio
16.12.4 Recent Development
16.13 Calliditas Therapeutics Ab
16.13.1 Company Snapshot
16.13.2 Pipeline Product Portfolio
16.13.3 Recent Development
16.14 Curevac Se
16.14.1 Company Snapshot
16.14.2 Revenue Analysis
16.14.3 Product Portfolio
16.14.4 Recent Development
16.15 Conatuspharma
16.15.1 Company Snapshot
16.15.2 Product Portfolio
16.15.3 Recent Development/News
16.16 Enanta Pharmaceuticals, Inc.
16.16.1 Company Snapshot
16.16.2 Revenue Analysis
16.16.3 Product Portfolio
16.16.4 Recent Development
16.17 Echosens
16.17.1 Company Snapshot
16.17.2 Product Portfolio
16.17.3 Recent Development/News
16.18 F. Hoffmann-la Roche Ltd
16.18.1 Company Snapshot
16.18.2 Revenue Analysis
16.18.3 Company Share Analysis
16.18.4 Product Portfolio
16.18.5 Recent Development
16.19 Galecto Biotech
16.19.1 Company Snapshot
16.19.2 Revenue Analysis
16.19.3 Pipeline Product Portfolio
16.19.4 Recent Development/News
16.20 Galectin Therapeutics, Inc.
16.20.1 Company Snapshots
16.20.2 Revenue Analysis And Segmental Analysis
16.20.3 Pipeline Product Portfolio
16.20.4 Recent Development
16.21 Gyre Therapeutics, Inc.
16.21.1 Company Snapshot
16.21.2 Revenue Analysis And Segmented Analysis
16.21.3 Product Portfolio
16.21.4 Recent Development/News
16.22 Genfit Sa
16.22.1 Company Snapshots
16.22.2 Revenue Analysis And Segmented Analysis
16.22.3 Pipeline Product Portfolio
16.22.4 Recent Development
16.23 Hepion Pharmaceuticals
16.23.1 Company Snapshot
16.23.2 Revenue Analysis
16.23.3 Pipeline Portfolio
16.23.4 Recent Development
16.24 Ipsen Pharma
16.24.1 Company Snapshot
16.24.2 Revenue Analysis
16.24.3 Pipeline Product Portfolio
16.24.4 Recent News/Developments
16.25 La Renon Healthcare Pvt. Ltd.
16.25.1 Company Snapshot
16.25.2 Product Portfolio
16.25.3 Recent Development
16.26 Madrigal Pharmaceuticals
16.26.1 Company Snapshots
16.26.2 Revenue Analysis And Segmented Analysis
16.26.3 Product Portfolio
16.26.4 Recent Development
16.27 Novo Nordisk A/S
16.27.1 Company Snapshot
16.27.2 Revenue Analysis
16.27.3 Pipeline Product Portfolio
16.27.4 Recent Development
16.28 Novomedix
16.28.1 Company Snapshot
16.28.2 Pipeline Product Portfolio
16.28.3 Recent Development
16.29 Pilant Therapeutics, Inc.
16.29.1 Company Snapshot
16.29.2 Revenue Analysis
16.29.3 Pipeline Product Portfolio
16.29.4 Recent News
16.30 Pfizer Inc.
16.30.1 Company Snapshot
16.30.2 Revenue Analysis
16.30.3 Pipeline Product Portfolio
16.30.4 Recent Development/News
16.31 Sagimet Biosciences
16.31.1 Company Snapshots
16.31.2 Revenue Analysis
16.31.3 1.1.4 Product Portfolio
16.31.4 Recent Development/News
16.32 Takeda Pharmaceutical Company Limited
16.32.1 Company Snapshot
16.32.2 Revenue Analysis
16.32.3 Pipeline Product Portfolio
16.32.4 Product Portfolio
16.32.5 Recent Development
16.33 Tvardi Therapeutics
16.33.1 Company Snapshot
16.33.2 Pipeline Product Portfolio
16.33.3 Recent Development/News
16.34 Vertex Pharmaceuticals Incorporated
16.34.1 Company Snapshot
16.34.2 Revenue Analysis
16.34.3 Product Portfolio
16.34.4 Recent Development
16.35 Viking Therapeutics
16.35.1 Company Snapshot
16.35.2 Revenue Analysis
16.35.3 Pipeline Product Portfolio
16.35.4 Recent Development
17 Questionnaire
18 Related Reports 492
List Of Tables
Table 1 Europe Incidence Of Cirrhosis By Gender (2019)
Table 2 Treatment Adherence Levels In Liver Disease Patients
Table 3 Europe Liver Fibrosis Treatment Market, By Treatment Type, 2018-2032 (Usd Thousand)
Table 4 Europe Medication In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 5 Europe Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 6 Europe Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 7 Europe Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 8 Europe Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 9 Europe Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 10 Europe Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 11 Europe Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 12 Europe Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 13 Europe Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 14 Europe Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 15 Europe Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 16 Europe Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 17 Europe Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 18 Europe Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 19 Europe Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 20 Europe Interleukin (Il) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 21 Europe Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 22 Europe Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 23 Europe Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 24 Europe Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 25 Europe Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 26 Europe Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 27 Europe Medication In Liver Fibrosis Treatment Market, By Drug Status, 2018-2032 (Usd Thousand)
Table 28 Europe Marketed Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 29 Europe Medication In Liver Fibrosis Treatment Market, By Drug Type, 2018-2032 (Usd Thousand)
Table 30 Europe Branded Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 31 Europe Medication In Liver Fibrosis Treatment Market, By Route Of Administration, 2018-2032 (Usd Thousand)
Table 32 Europe Surgery/Therapy In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 33 Europe Surgery/Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 34 Europe Liver Transplantation In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 35 Europe Endoscopic & Minimally Invasive Procedures In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 36 Europe Liver Ablation Procedures In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 37 Europe Partial Hepatectomy (Liver Resection) In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 38 Europe Cell-based Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 39 Europe Stem Cell Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 40 Europe Gene Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 41 Europe Hepatocyte Apoptosis Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 42 Europe Liver Fibrosis Treatment Market, By Stages, 2018-2032 (Usd Thousand)
Table 43 Europe F2 In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 44 Europe F1 In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 45 Europe F3 In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 46 Europe F4 In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 47 Europe Liver Fibrosis Treatment Market, By Indication, 2018-2032 (Usd Thousand)
Table 48 Europe Non-alcoholic Steatohepatitis (Nash) In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 49 Europe Hepatitis B & C-induced Fibrosis In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 50 Europe Hepatitis B & C-induced Fibrosis In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 51 Europe Alcoholic Liver Disease (Ald) In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 52 Europe Autoimmune Liver Diseases In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 53 Europe Autoimmune Liver Diseases In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 54 Europe Genetic Disorders In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 55 Europe Genetic Disorders In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 56 Europe Others In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 57 Europe Liver Fibrosis Treatment Market, By Gender, 2018-2032 (Usd Thousand)
Table 58 Europe Male In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 59 Europe Male In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 60 Europe Female In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 61 Europe Female In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 62 Europe Liver Fibrosis Treatment Market, By End User, 2018-2032 (Usd Thousand)
Table 63 Europe Hospitals In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 64 Europe Hospitals In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 65 Europe Specialty Clinics In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 66 Europe Specialty Clinics In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 67 Europe Clinics In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 68 Europe Ambulatory And Research Centers In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 69 Europe Others In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 70 Europe Liver Fibrosis Treatment Market, By Distribution Channel, 2018-2032 (Usd Thousand)
Table 71 Europe Direct Tender In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 72 Europe Retail Sales In Liver Fibrosis Treatment Market, By Region, 2018-2032 (Usd Thousand)
Table 73 Europe Retail Sales In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 74 Europe Liver Fibrosis Treatment Market, By Country, 2018-2032 (Usd Thousand)
Table 75 Europe Liver Fibrosis Treatment Market, By Treatment Type, 2018-2032 (Usd Thousand)
Table 76 Europe Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 77 Europe Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 78 Europe Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 79 Europe Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 80 Europe Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 81 Europe Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 82 Europe Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 83 Europe Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 84 Europe Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 85 Europe Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 86 Europe Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 87 Europe Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 88 Europe Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 89 Europe Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 90 Europe Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 91 Europe Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 92 Europe Interleukin (Il) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 93 Europe Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 94 Type
Table 95 Europe Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 96 Europe Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 97 Europe Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 98 Europe Medication In Liver Fibrosis Treatment Market, By Drug Status, 2018-2032 (Usd Thousand)
Table 99 Europe Marketed Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 100 Europe Medication In Liver Fibrosis Treatment Market, By Drug Type, 2018-2032 (Usd Thousand)
Table 101 Europe Branded Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 102 Europe Medication In Liver Fibrosis Treatment Market, By Route Of Administration, 2018-2032 (Usd Thousand)
Table 103 Europe Surgery/Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 104 Europe Liver Transplantation In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 105 Europe Endoscopic & Minimally Invasive Procedures In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 106 Europe Liver Ablation Procedures In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 107 Europe Partial Hepatectomy (Liver Resection) In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 108 Europe Cell-based Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 109 Europe Stem Cell Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 110 Europe Gene Therapy In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 111 Europe Hepatocyte Apoptosis Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 112 Europe Liver Fibrosis Treatment Market, By Stages, 2018-2032 (Usd Thousand)
Table 113 Europe Liver Fibrosis Treatment Market, By Indication, 2018-2032 (Usd Thousand)
Table 114 Europe Hepatitis B & C-induced Fibrosis In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 115 Europe Autoimmune Liver Diseases In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 116 Europe Genetic Disorders In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 117 Europe Liver Fibrosis Treatment Market, By Gender, 2018-2032 (Usd Thousand)
Table 118 Europe Male In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 119 Europe Female In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 120 Europe Liver Fibrosis Treatment Market, By End User, 2018-2032 (Usd Thousand)
Table 121 Europe Hospitals In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 122 Europe Specialty Clinics In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 123 Europe Liver Fibrosis Treatment Market, By Distribution Channel, 2018-2032 (Usd Thousand)
Table 124 Europe Retail Sales In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 125 Germany Liver Fibrosis Treatment Market, By Treatment Type, 2018-2032 (Usd Thousand)
Table 126 Germany Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 127 Germany Medication In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 128 Germany Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 129 Germany Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 130 Germany Antiviral Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 131 Germany Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 132 Germany Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 133 Germany Antifibrotic Agents In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 134 Germany Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 135 Germany Anti-inflammatory Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 136 Germany Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 137 Germany Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 138 Germany Corticosteroids In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 139 Germany Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 140 Germany Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 141 Germany Tumor Necrosis Factor (Tnf) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 142 Germany Interleukin (Il) Inhibitors In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 143 Germany Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 144 Germany Interleukin (Il) Inhibitor In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 145 Germany Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
Table 146 Germany Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Volume In Thousand Units)
Table 147 Germany Immunosuppressants In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Asp In Usd/Units)
Table 148 Germany Medication In Liver Fibrosis Treatment Market, By Drug Status, 2018-2032 (Usd Thousand)
Table 149 Germany Marketed Drugs In Liver Fibrosis Treatment Market, By Type, 2018-2032 (Usd Thousand)
List Of Figures
Figure 1 Middle East And Africa Liver Fibrosis Treatment Market: Segmentation
Figure 2 Middle East And Africa Liver Fibrosis Treatment Market: Data Triangulation
Figure 3 Middle East And Africa Liver Fibrosis Treatment Market: Droc Analysis
Figure 4 Middle East And Africa Liver Fibrosis Treatment Market: Regional Market Analysis
Figure 5 Middle East And Africa Liver Fibrosis Treatment Market: Company Research Analysis
Figure 6 Middle East And Africa Liver Fibrosis Treatment Market: Interview Demographics
Figure 7 Middle East And Africa Liver Fibrosis Treatment Market: Dbmr Market Position Grid
Figure 8 Middle East And Africa Liver Fibrosis Treatment Market: Market End User Coverage Grid
Figure 9 Middle East And Africa Liver Fibrosis Treatment Market: Vendor Share Analysis
Figure 10 Middle East And Africa Liver Fibrosis Treatment Market: Segmentation
Figure 11 Increasing Prevalence Of Liver Diseases Is Expected To Drive The Growth Of Middle East And Africa Liver Fibrosis Treatment Market From 2025 To 2032
Figure 12 The Medication Segment Is Expected To Account For The Largest Share Of The Middle East And Africa Liver Fibrosis Treatment Market In 2025-2032
Figure 13 Two Segments Comprise The Middle East And Africa Liver Fi

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us